$218 Million is the total value of Stonepine Capital Management, LLC's 23 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 77.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMYT | Buy | AMRYT PHARMA PLC - SPNR ADRsponsored ads | $65,554,000 | -6.2% | 6,069,775 | +4.6% | 30.08% | -5.4% |
| CTIC | Buy | CTI BIOPHARMA CORP | $21,825,000 | -7.1% | 8,800,358 | +10.5% | 10.02% | -6.3% |
| New | XERIS BIOPHARMA HOLDINGS INC | $16,573,000 | – | 5,656,373 | +100.0% | 7.60% | – | |
| ADMA | New | ADMA BIOLOGICS INC | $13,975,000 | – | 9,911,577 | +100.0% | 6.41% | – |
| OVID | Buy | OVID THERAPEUTICS INC | $12,860,000 | +17.7% | 4,006,185 | +23.2% | 5.90% | +18.6% |
| EOLS | Buy | EVOLUS INC | $12,129,000 | +430.6% | 1,863,096 | +521.0% | 5.57% | +435.2% |
| CFMS | Buy | CONFORMIS INC | $11,245,000 | +1635.3% | 14,768,823 | +2932.7% | 5.16% | +1649.2% |
| XGN | Buy | EXAGEN INC | $9,985,000 | +87.9% | 858,567 | +119.8% | 4.58% | +89.5% |
| APEN | Buy | APOLLO ENDOSURGERY INC | $9,704,000 | +17.4% | 1,151,163 | +26.2% | 4.45% | +18.4% |
| ATRS | Buy | ANTARES PHARMA INC | $8,202,000 | +753.5% | 2,297,360 | +769.9% | 3.76% | +761.3% |
| OPTN | New | OPTINOSE INC | $6,228,000 | – | 3,844,230 | +100.0% | 2.86% | – |
| DMAC | Buy | DIAMEDICA THERAPEUTICS INC | $4,456,000 | +570.1% | 1,194,670 | +620.7% | 2.04% | +574.9% |
| LIFE | Buy | ATYR PHARMA INC | $3,926,000 | +5.3% | 525,531 | +28.0% | 1.80% | +6.2% |
| RZLT | New | REZOLUTE INC | $3,864,000 | – | 808,405 | +100.0% | 1.77% | – |
| CELC | Sell | CELCUITY INC | $3,158,000 | -40.5% | 239,433 | -18.8% | 1.45% | -40.0% |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $2,936,000 | +67.4% | 2,311,530 | +195.3% | 1.35% | +68.8% |
| SYBX | Buy | SYNLOGIC INC | $2,575,000 | -15.6% | 1,064,135 | +6.4% | 1.18% | -14.8% |
| Buy | AVALO THERAPEUTICS INC | $2,567,000 | +38.5% | 1,510,095 | +77.7% | 1.18% | +39.7% | |
| ANIP | New | ANI PHARMACEUTICALS INC | $2,410,000 | – | 52,290 | +100.0% | 1.11% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $1,014,000 | – | 300,000 | +100.0% | 0.46% | – |
| NMTC | New | NEUROONE MEDICAL TECHNOLOGIES CORPORATION | $967,000 | – | 498,354 | +100.0% | 0.44% | – |
| XOMA | Sell | XOMA CORP | $960,000 | -43.4% | 46,026 | -32.8% | 0.44% | -42.9% |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $800,000 | – | 200,000 | +100.0% | 0.37% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -6,327 | -100.0% | -0.02% | – |
| SPNE | Exit | SEASPINE HOLDINGS CORP | $0 | – | -8,349 | -100.0% | -0.06% | – |
| CFRX | Exit | CONTRAFECT CORP | $0 | – | -34,413 | -100.0% | -0.06% | – |
| IMUX | Exit | IMMUNIC INC | $0 | – | -22,409 | -100.0% | -0.09% | – |
| NBSE | Exit | NEUBASE THERAPEUTICS INC | $0 | – | -109,742 | -100.0% | -0.18% | – |
| EYPT | Exit | EYEPOINT PHARMACEUTICALS INC | $0 | – | -80,537 | -100.0% | -0.38% | – |
| LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.46% | – |
| ANGN | Exit | ANGION BIOMEDICA CORP | $0 | – | -280,183 | -100.0% | -1.24% | – |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -1.59% | – |
| YMTX | Exit | YUMANITY THERAPEUTICS INC | $0 | – | -481,692 | -100.0% | -2.26% | – |
| GMDA | Exit | GAMIDA CELL LTD | $0 | – | -1,724,201 | -100.0% | -3.08% | – |
| AFMD | Exit | AFFIMED NV | $0 | – | -1,161,466 | -100.0% | -3.27% | – |
| SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -4,489,687 | -100.0% | -4.17% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -2,635,014 | -100.0% | -4.93% | – |
| GLPG | Exit | GALAPAGOS NV-SPON ADRspons adr | $0 | – | -244,205 | -100.0% | -5.85% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -3,914,938 | -100.0% | -8.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.